Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_sessionrnfe979itqtl05poi8ckrpipijsksloo): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
82 results match your criteria: "Antoine Béclère Hospital (AP-HP)[Affiliation]"
Clin Lymphoma Myeloma Leuk
September 2024
Service d'hématologie, Hôpital Haut-Lévêque, Bordeaux, Pessac.
Introduction: Multiple myeloma patients aged 80 years and older are a population more prone to comorbidities and frailty. We aim to describe the real-life management and outcomes of this population. EMMY is a descriptive large-scale study.
View Article and Find Full Text PDFEur J Cancer
November 2024
University of Lorraine, Department of Hepato-Gastroenterology and digestive oncology, Nancy University Hospital, Nancy, France. Electronic address:
Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. The POLO trial showed that olaparib (PARP inhibitor) improved progression-free survival (PFS) but not overall survival (OS), when used as maintenance therapy after ≥ 16 weeks of disease control with first-line platinum-based chemotherapy in patients with germline (g) BRCA 1 or 2 pathogenic variants (PV) metastatic PDAC. However, real-world data on the effectiveness of olaparib are missing.
View Article and Find Full Text PDFJoint Bone Spine
September 2024
Department of Rheumatology, Saint-Antoine Hospital (AP-HP), 184, rue du Faubourg Saint-Antoine, 75012 Paris, France; Inserm UMRS_938, Paris Center for Microbiome Medicine (PaCeMM) FHU, Centre de recherche Saint-Antoine, Sorbonne université, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France. Electronic address:
Hepatol Commun
July 2024
Team "Viruses, Hepatology, Cancer", Institut Mondor de Recherche Biomédicale, INSERM U955, Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France.
Background: Selective internal radiation therapy (SIRT) is recommended as a downstaging (DS) strategy for solitary unresectable HCC <8 cm. The aim of this study was to report the results of acquired experience in a tertiary center for all unresectable HCCs.
Methods: We conducted a retrospective, observational study using data collected from consecutive patients undergoing SIRT between October 2013 and June 2020.
Front Med (Lausanne)
June 2024
Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), AP-HP, Paris, France.
Background: The COVID-19 pandemic related to SARS-CoV-2 virus was responsible for global pandemic. The severe form of the disease was linked to excessive activation of immune pathways together with a systemic cytokine storm response and thrombotic venous or arterial complications. Factors predicting severe outcomes including venous and/or pulmonary thrombosis (VT) and death were identified, but the prognostic role of their combination was not addressed extensively.
View Article and Find Full Text PDFLancet Child Adolesc Health
August 2024
My FetUZ Research Group, Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, KU Leuven, Leuven, Belgium; Institute for Women's Health, University College London, London, UK; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium. Electronic address:
Background: Temporary fetoscopic endoluminal tracheal occlusion (FETO) promotes lung growth and increases survival in selected fetuses with congenital diaphragmatic hernia (CDH). FETO is performed percutaneously by inserting into the trachea a balloon designed for vascular occlusion. However, reports on the potential postnatal side-effects of the balloon are scarce.
View Article and Find Full Text PDFAnn Oncol
September 2024
Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France. Electronic address:
Background: After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of gemcitabine (GEM)-based regimens or the modified FOLFIRINOX (mFFX) regimen. While mFFX regimen has been shown to be more effective than GEM-based regimens, it is also associated with higher toxicity. Current treatment decisions are based on patient performance status rather than on the molecular characteristics of the tumor.
View Article and Find Full Text PDFArtif Organs
August 2024
Department of Hepatobiliary Surgery and Liver Transplantation, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Context: Clinical adoption of ex situ liver perfusion is growing. While hypothermic perfusion protects against ischemia-reperfusion injury in marginal grafts, normothermic perfusion enables organ viability assessment and therefore selection of borderline grafts. The combination of hypothermic and normothermic perfusion, known as "cold-to-warm," may be the optimal sequence for organ preservation, but is difficult to achieve with most commercial perfusion systems.
View Article and Find Full Text PDFGastrointest Endosc
September 2024
Center for digestive endoscopy, Sorbonne University, Saint Antoine Hospital, APHP Paris, Paris, France.
Background And Aims: Small-bowel (SB) capsule endoscopy (CE) is a first-line procedure for exploring the SB. Endoscopic GI PlacemenT (EGIPT) of SB CE is sometimes necessary. Although experience with EGIPT is considerable in pediatric populations, we aimed to describe the safety, efficacy, and outcomes of EGIPT of SB CE in adult patients.
View Article and Find Full Text PDFAnn Endocrinol (Paris)
February 2024
Endocrinology Department, INSERM Unit 1215, Bordeaux University Hospital, University of Bordeaux, Bordeaux, France. Electronic address:
Ther Adv Med Oncol
August 2023
Gastroenterology and Digestive Oncology Unit, Cochin Hospital AP-HP, Paris, France.
Am J Med
August 2023
Department of Hepato-Gastroenterology, Tenon Hospital (AP-HP), Paris, France.
Clin Hematol Int
March 2023
Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
Haematologica
November 2023
Université de Paris Cité, Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris.
Clin Rheumatol
July 2023
Nuclear Medicine & PET/CT Center, Tenon Hospital (AP-HP), Paris, France.
Asian J Androl
July 2023
Reproductive Biology and CECOS, Tenon Hospital (AP-HP), Sorbonne-Université, Paris 75020; Sorbonne University, Research Center Saint-Antoine, Inserm US938, Paris 7501, France.
Therapie
October 2022
Department of Internal Medicine and Clinical Immunology, CHRU Tours, 37044 Tours, France; University of Tours, 37000 Tours, France; LabEx MabImprove, 37000 Tours, France.
Introduction: Rituximab is a chimeric anti-CD20 antibody commonly used to treat patients with autoimmune diseases. Such diseases mainly affect young people, but older patients may also be concerned. So far, very little data exist concerning the safety of rituximab in older patients with autoimmune diseases.
View Article and Find Full Text PDFJ Am Heart Assoc
September 2022
Université Paris Cité Inserm, PARCC, F-75015 Paris France.
Background Little data are available in women presenting with ventricular fibrillation (VF) in the setting of acute myocardial infarction (AMI). We assessed frequency, predictors of VF, and outcomes, with a special focus on women compared with men. Methods and Results Data were analyzed from the FAST-MI (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) program, which prospectively included 14 406 patients admitted to French cardiac intensive care units ≤48 hours from AMI onset between 1995 and 2015 (mean age, 66±14 years; 72% men; mean left ventricular ejection fraction, 52±12%; 59% with ST-segment-elevation myocardial infarction).
View Article and Find Full Text PDFBull World Health Organ
June 2022
Directorate of Education, Tishreen University, Lattakia, Syria.
Bone Marrow Transplant
August 2022
University Medical Center Hamburg, Hamburg, Germany.
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres.
View Article and Find Full Text PDFLancet Haematol
May 2022
Division of Haematology, Mayo Clinic, Rochester, MN, USA.
Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted agents, immune and cellular therapies, and combination regimens have adverse event profiles distinct from conventional finite cytotoxic chemotherapies. In 2018, a Commission comprising patient advocates, clinicians, clinical investigators, regulators, biostatisticians, and pharmacists representing a broad range of academic and clinical cancer expertise examined issues of adverse event evaluation in the context of both newer and existing therapies for haematological cancers.
View Article and Find Full Text PDFMorgagni's hernia is a congenital diaphragmatic hernia, which represents only 3% of all diaphragmatic hernias. Herein, we report a case of a 28-year-old symptomatic female patient with Morgagni's hernia who underwent a transabdominal surgery for hernia repair and mesh placement.
View Article and Find Full Text PDFFront Oncol
February 2022
Unit of Blood Diseases and Stem Cell Transplantation, ASST-Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
N Engl J Med
March 2022
From the Department of Nuclear Medicine and Endocrine Oncology (S.L., L. Lamartina, M.-J.S.), the Department of Medical Biology and Pathology (A.A.G., L. Lacroix), and the Biostatistics and Epidemiology Office, Oncostat, INSERM Unité 1018 (I.B.), Gustave Roussy and Université Paris-Saclay, Villejuif, the Nuclear Medicine Department, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron (C.B.), the Endocrine Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP) Hôpital Saint-Louis (C.N.C.), and the Thyroid and Endocrine Tumors Unit, Pitié-Salpétrière Hospital AP-HP, Institute of Cancer IUC Sorbonne University (L. Leenhardt), Paris, the Department of Medical Imaging, Nuclear Medicine, IUCT Oncopole Toulouse-Institut Claudius Regaud (S.Z.), and the Nuclear Medicine Department, CHU Rangueil (D. Bastie), Toulouse, the Department of Endocrinology-Metabolic Diseases, Hôpital Saint-André, Centre Hospitalier Universitaire (CHU) de Bordeaux (B.C.), and the Thyroid Oncology and Nuclear Medicine Department, Institut Bergonié (Y.G.), Bordeaux, the Endocrine Department, CHRU de Lille-Hôpital Claude Huriez, Lille (C.D.C.), the Nuclear Medicine Department, Centre Jean Perrin, Clermont-Ferrand (A.K.), the Nuclear Medicine Department, Centre Eugene Marquis, Rennes (M.-L.B.), the Nuclear Medicine Department, Centre Georges François Leclerc, Dijon (I.D.), the Nuclear Medicine Department, Centre Henri Becquerel and Laboratoire QUANTif, Rouen (P.V.), the Nuclear Medicine Department, Centre René Gauducheau, Saint Herblain (D.R.), the Nuclear Medicine Department, Centre Paul Strauss, Strasbourg (O.S.), the Nuclear Medicine Department, Antoine Lacassagne, Nice (D. Benisvy), the Endocrine Department, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, Hôpitaux de Brabois, Vandoeuvre Les Nancy (M.K.), the Nuclear Medicine Department, CHU Grenoble-Alpes, Grenoble (J.R.), the Nuclear Medicine Department, Institut du Cancer de Montpellier, Institut Régional du Cancer Val d'Aurelle, Montpellier (M.-C.E.), the Nuclear Medicine Department, Institut Curie Site Saint-Cloud, Saint-Cloud (C.N.), the Nuclear Medicine Department, Centre Léon Bérard, Lyon (A.-L.G.), the Endocrine Department, CHU Saint Pierre, Saint Pierre (N.L.M.), the Nuclear Medicine Department and Thyroid Unit, Centre François Baclesse, Caen (S.B.), the Endocrine Department, Institut du Thorax, CHU de Nantes-Hopital Laennec Saint-Herblain, Nantes (D.D.), the Endocrine Department, CHU La Cavale Blanche, Brest (N.R.), the Nuclear Medicine Department, Institut de Cancérologie de l'Ouest, Angers (O.M.), the Endocrine Department, CHU Dupuytren, Limoges (A.D.), the Thyroid Unit, Institut Jean Godinot, Reims (C.S.), and the Endocrine Department, CHU de Guadeloupe, Hôpital Ricou, Les Abymes (F.-L.V.) - all in France.
Background: In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, the postoperative administration of radioiodine (iodine-131) is controversial in the absence of demonstrated benefits.
Methods: In this prospective, randomized, phase 3 trial, we assigned patients with low-risk differentiated thyroid cancer who were undergoing thyroidectomy to receive ablation with postoperative administration of radioiodine (1.1 GBq) after injections of recombinant human thyrotropin (radioiodine group) or to receive no postoperative radioiodine (no-radioiodine group).
Asian J Androl
November 2022
Fertility Center (Service de Biologie de la Reproduction CECOS), Tenon Hospital (AP-HP, Sorbonne-Université), Paris F-75020, France.
Advances in the oncology field have led to improved survival rates. Consequently, quality of life after remission is anticipated, which includes the possibility to conceive children. Since cancer treatments are potentially gonadotoxic, fertility preservation must be proposed.
View Article and Find Full Text PDF